What are the reasons for discontinuing gabapentin in an 82‑year‑old female patient?

Reasons for Discontinuing Gabapentin in an 82-Year-Old Female

Gabapentin should be discontinued in an 82-year-old female if it is causing falls, dizziness, somnolence, cognitive impairment, or if it was prescribed for an indication not supported by guidelines—particularly for non-neuropathic pain conditions.

Primary Safety Concerns in Older Adults

Falls and Fractures Risk

The FDA explicitly warns that gabapentin causes somnolence (19-21%), dizziness (17-28%), and ataxia (13%) at significantly higher rates than placebo 1. In a large cohort study of 571,718 veterans, gabapentin exposure increased the risk of falls or fractures by 35% (RR 1.35,95% CI 1.28-1.44), with a clear dose-response relationship—the highest risk occurred at doses ≥2,400 mg/day (RR 1.90) 2. At age 82, even a single fall can be catastrophic, leading to hip fracture, loss of independence, or death.

Central Nervous System Depression

Gabapentin increases the risk of altered mental status (RR 1.12) 2, and the FDA warns about driving impairment, cognitive dysfunction, and inability to operate machinery 1. Visual hallucinations have been documented even at standard doses 3. In geriatric patients, these CNS effects are magnified and can precipitate delirium or worsen pre-existing cognitive impairment.

Drug Interactions and Polypharmacy

The FDA specifically warns that gabapentin has synergistic CNS depression when combined with other sedating medications 1. In an 82-year-old likely taking multiple medications, this interaction risk is substantial. When combined with opioids, gabapentin can cause dangerous respiratory depression 4.

Guideline-Based Indications

When Discontinuation is Appropriate

Recent guideline analysis shows that 62% of gabapentinoid prescriptions for pain in geriatric patients are not supported by guidelines 5. The STOPPFrail 2021 criteria indicate that gabapentin should be questioned or discontinued in frail older adults with limited life expectancy unless specifically prescribed for neuropathic pain 6.

Discontinue if prescribed for:

• Non-specific chronic pain without documented neuropathy
• Musculoskeletal pain
• Generalized pain syndromes
• Off-label uses without clear benefit

Consider continuation only for:

• Documented postherpetic neuralgia
• Painful diabetic neuropathy
• Other confirmed neuropathic pain conditions

Long-Term Use and Dependence

Approximately 50% of patients on gabapentin have been treated continuously for at least 12 months, a practice often not recommended by guidelines 4. The FDA warns that abrupt discontinuation can precipitate withdrawal seizures and status epilepticus 1. Case reports document severe gabapentin dependence requiring 18-month tapers 7, and withdrawal symptoms include anxiety, insomnia, nausea, pain, and sweating 1.

If discontinuing, you must taper slowly:

• Reduce by 100 mg per month initially
• Slow to 20-30 mg decrements per month at lower doses
• Final 100 mg may require 5 mg decrements every 1-2 weeks
• Never stop abruptly

Additional Adverse Effects in Elderly

• Peripheral edema (8% vs 2% placebo) 1—problematic in patients with heart failure or venous insufficiency
• Hypoglycemia—rare but documented, especially in pre-diabetic or diabetic patients 8
• Increased suicidal ideation risk (FDA black box warning) 1
• DRESS syndrome and anaphylaxis—rare but potentially fatal 1

Clinical Decision Algorithm

1. Assess the indication: Is gabapentin prescribed for guideline-supported neuropathic pain? If no → strong candidate for discontinuation
2. Evaluate adverse effects: Is the patient experiencing falls, dizziness, confusion, or sedation? If yes → discontinue
3. Review polypharmacy: Is the patient on opioids or other CNS depressants? If yes → heightened risk, consider discontinuation
4. Consider frailty status: Is the patient frail (CFS ≥5) or with limited life expectancy? If yes → questionable benefit per STOPPFrail 6
5. If discontinuing: Implement slow taper over months to avoid withdrawal seizures

Common Pitfalls

• Abrupt discontinuation: Always taper to prevent withdrawal seizures 1
• Ignoring dose-response: Risk increases substantially at doses ≥600 mg/day 2
• Continuing without reassessment: Many patients remain on gabapentin indefinitely without documented benefit 4, 5
• Overlooking drug interactions: Always check for concurrent opioids or benzodiazepines 4, 1

The default position for an 82-year-old should be discontinuation unless there is clear, documented neuropathic pain with demonstrable benefit that outweighs the substantial fall and cognitive risks.